---
title: "TriSalus Life Sciences - CW | 10-Q: FY2025 Q1 Revenue: USD 9.167 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240371639.md"
datetime: "2025-05-15T11:56:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240371639.md)
  - [en](https://longbridge.com/en/news/240371639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240371639.md)
---

# TriSalus Life Sciences - CW | 10-Q: FY2025 Q1 Revenue: USD 9.167 M

Revenue: As of FY2025 Q1, the actual value is USD 9.167 M.

EPS: As of FY2025 Q1, the actual value is USD -0.39.

### Segment Revenue

-   **Revenue**: $9,167 thousand for the three months ended March 31, 2025, compared to $6,457 thousand for the same period in 2024, representing a 42.0% increase.

### Operational Metrics

-   **Gross Profit**: $7,672 thousand for the three months ended March 31, 2025, compared to $5,486 thousand for the same period in 2024.
-   **Gross Margin**: 83.7% for the three months ended March 31, 2025, compared to 85.0% for the same period in 2024.
-   **Loss from Operations**: - $7,329 thousand for the three months ended March 31, 2025, compared to - $11,672 thousand for the same period in 2024.
-   **Net Loss**: - $10,375 thousand for the three months ended March 31, 2025, compared to - $13,206 thousand for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $4,499 thousand for the three months ended March 31, 2025, compared to - $10,867 thousand for the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $714 thousand for the three months ended March 31, 2025, compared to - $66 thousand for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $9,688 thousand for the three months ended March 31, 2025, compared to $3,126 thousand for the same period in 2024.

### Unique Metrics

-   **Undeclared Dividends on Series A Preferred Stock**: - $712 thousand for the three months ended March 31, 2025, compared to - $801 thousand for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue the commercialization of TriNav and expand its PEDD device portfolio with the TriNav LV Infusion System and TriGuide Guiding Catheter, targeting larger vessel sizes.
-   **Non-Core Business**: TriSalus is exploring partnerships for further clinical development of nelitolimod, following Phase I trials.
-   **Priority**: The company aims to achieve a trailing 12-month Product Revenue Base of $50 million by December 31, 2025, to access additional funding under the OrbiMed Credit Agreement.

### Related Stocks

- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Shein Locks In August 28 for $30 Billion Hong Kong IPO, Sources Say](https://longbridge.com/en/news/295783911.md)
- [Oil steadies after US threatens indefinite blockade of Iran](https://longbridge.com/en/news/295876144.md)
- [Novo CEO says obesity market won't be winner-take-all battle with Lilly](https://longbridge.com/en/news/295777893.md)
- [164,534 Shares in Hewlett Packard Enterprise Company $HPE Purchased by Counterpoint Mutual Funds LLC](https://longbridge.com/en/news/295765181.md)
- [Avior Wealth Management LLC Decreases Stake in Alphabet Inc. $GOOGL](https://longbridge.com/en/news/295757955.md)